Torrent Pharmaceuticals Limited (BOM: 500420)
India
· Delayed Price · Currency is INR 3,436.80
0.00 (0.00%)
At close: Sep 11, 2024
Torrent Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Net Income | - | 16,564 | 12,452 | 7,772 | 12,519 | 10,247 | Upgrade
|
| Depreciation & Amortization | - | 7,748 | 6,830 | 6,427 | 6,399 | 6,299 | Upgrade
|
| Other Amortization | - | 204.6 | 190.3 | 192.8 | 174 | 216.1 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | 0.2 | -216.2 | 8.2 | 13 | 257.3 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 129.7 | 45.6 | 2.3 | 4.8 | 28.7 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | -179.9 | -195.1 | -101.4 | -155.8 | -292 | Upgrade
|
| Provision & Write-off of Bad Debts | - | 70.8 | 22.7 | 9 | 144.2 | 26.4 | Upgrade
|
| Other Operating Activities | - | 3,942 | 4,734 | 7,239 | 4,338 | 1,005 | Upgrade
|
| Change in Accounts Receivable | - | 783.2 | -2,897 | -1,091 | 652.1 | -1,780 | Upgrade
|
| Change in Inventory | - | -494.3 | 2,557 | 2,189 | -5,330 | -2,131 | Upgrade
|
| Change in Accounts Payable | - | 4,136 | -580.2 | -3,924 | 1,295 | 51.9 | Upgrade
|
| Change in Other Net Operating Assets | - | -243.6 | 738.3 | -692.5 | - | - | Upgrade
|
| Operating Cash Flow | - | 32,661 | 23,681 | 18,030 | 20,054 | 13,929 | Upgrade
|
| Operating Cash Flow Growth | - | 37.92% | 31.34% | -10.09% | 43.97% | -22.53% | Upgrade
|
| Capital Expenditures | - | -4,328 | -5,739 | -2,026 | -3,352 | -4,068 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 1,337 | 1,587 | 67.9 | 11.3 | 39.5 | Upgrade
|
| Cash Acquisitions | - | - | -20,000 | - | - | - | Upgrade
|
| Investment in Securities | - | 1,181 | -129.8 | -80.9 | -1,207 | 5,846 | Upgrade
|
| Other Investing Activities | - | 131.2 | 129 | 72.4 | 52.5 | 168.6 | Upgrade
|
| Investing Cash Flow | - | -1,679 | -24,153 | -1,966 | -4,494 | 1,986 | Upgrade
|
| Short-Term Debt Issued | - | - | 8,420 | 2,186 | - | 1,381 | Upgrade
|
| Long-Term Debt Issued | - | - | 13,950 | - | 8,950 | 7,500 | Upgrade
|
| Total Debt Issued | - | - | 22,370 | 2,186 | 8,950 | 8,881 | Upgrade
|
| Short-Term Debt Repaid | - | -1,334 | - | - | -3,789 | - | Upgrade
|
| Long-Term Debt Repaid | - | -12,599 | -9,936 | -10,651 | -14,724 | -12,333 | Upgrade
|
| Total Debt Repaid | - | -13,933 | -9,936 | -10,651 | -18,513 | -12,333 | Upgrade
|
| Net Debt Issued (Repaid) | - | -13,933 | 12,434 | -8,464 | -9,563 | -3,452 | Upgrade
|
| Common Dividends Paid | - | -10,153 | -5,132 | -6,769 | -3,385 | -3,236 | Upgrade
|
| Other Financing Activities | - | -3,710 | -3,030 | -2,577 | -3,561 | -5,947 | Upgrade
|
| Financing Cash Flow | - | -27,796 | 773.6 | -17,811 | -16,508 | -15,490 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | 80.7 | 211.2 | 5.3 | 56 | 305.8 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | 588.3 | - | - | - | Upgrade
|
| Net Cash Flow | - | 3,266 | 1,101 | -1,742 | -892.6 | 730.6 | Upgrade
|
| Free Cash Flow | - | 28,333 | 17,942 | 16,004 | 16,702 | 9,861 | Upgrade
|
| Free Cash Flow Growth | - | 57.92% | 12.11% | -4.18% | 69.37% | -13.14% | Upgrade
|
| Free Cash Flow Margin | - | 26.41% | 18.65% | 18.81% | 20.87% | 12.42% | Upgrade
|
| Free Cash Flow Per Share | - | 83.72 | 53.01 | 47.29 | 49.35 | 29.14 | Upgrade
|
| Cash Interest Paid | - | 3,710 | 3,030 | 2,577 | 3,561 | 4,854 | Upgrade
|
| Cash Income Tax Paid | - | 4,981 | 3,981 | 4,210 | 1,755 | 3,933 | Upgrade
|
| Levered Free Cash Flow | - | 22,213 | 14,783 | 10,209 | 7,970 | 3,480 | Upgrade
|
| Unlevered Free Cash Flow | - | 24,417 | 16,860 | 11,790 | 10,163 | 6,282 | Upgrade
|
| Change in Net Working Capital | - | -4,714 | -2,204 | 3,862 | 4,451 | 5,658 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.